Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Raises Zocor 2006 Guidance By $300 Mil.

This article was originally published in The Pink Sheet Daily

Executive Summary

Given the introduction of generic simvastatin, the company remains positive on sales of Zocor.

You may also be interested in...



Teva And Ranbaxy Launch Generic Zocor With 180-Day Exclusivity

Despite an eleventh-hour suit by Sandoz, FDA approved the generic companies’ ANDAs for simvastatin.

Merck Extends Shelf Life Of Branded Zocor Through Rebate Deal With UnitedHealth

Sen. Schumer demands FTC investigation over Merck's alleged "anti-competitive" actions.

NEJM, JAMA Editorials Give Opposing Opinions Of Mandatory HPV Vaccination

Two of the leading medical journals are offering opposing viewpoints on mandatory human papilloma virus vaccination, with experts contributing perspective pieces that directly reflect the larger political and social division over the issue

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS064565

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel